Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.60 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.59 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.59 |
| ▸ | CDK9 | P50750 | 1/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.59 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.59 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.59 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525642 | 0.87 | HRH3 (0.56) | HRH3DYRK3CCNT1CDK9DYRK1A | |
| SCHEMBL13606217 | 0.87 | CNR2 (0.51) | AOC3CNR2 | |
| SCHEMBL3525055 | 0.82 | HRH3 (0.51) | HRH3AOC3 | |
| SCHEMBL10900792 | 0.82 | AOC3 (0.54) | DYRK3CCNT1CDK9DYRK1ADYRK2 | |
| SCHEMBL3524232 | 0.80 | DKK1 (0.46) | HRH3 | |
| SCHEMBL3525447 | 0.80 | HRH3 (0.61) | HRH3 | |
| SCHEMBL19496965 | 0.79 | AOC3 (0.61) | HRH3AOC3 | |
| SCHEMBL5912918 | 0.75 | DYRK3 (0.45) | HRH3DYRK3CCNT1CDK9DYRK1A | |
| SCHEMBL12244706 | 0.74 | HRH3 (0.64) | HRH3DYRK3CCNT1CDK9DYRK1A | |
| SCHEMBL14529001 | 0.74 | L3MBTL3 (0.65) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834182-B2 | histamine H3 receptor antagonists; metabolic disorders, sleep disorders, cardiovascular disorders, alcoholism, drug addiction, memory disorders, Alzheimer's, Parkinson's disease; 2-(4-piperidinylpiperidinyl)pyrimidine compounds such as 2-[(4-piperidin-1-yl)piperidin-1-yl]-5-(3-pyridyl)pyrimidine | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20090203710-A1 | Novel piperidine derivative | MSD K.K. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-7547693-B2 | Such as N-methyl-N-(1-methylpiperidin-4-yl)-4-[4-(piperidin-1-yl)piperidin-1-yl]benzamide; histamine h3-antagonists | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20070105901-A1 | Novel piperidine derivative | MSD K.K. (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105901-A1 | Novel piperidine derivative | HRH3, OPRM1, OPRK1 | HRH3 1/4885DYRK3 4209/4885CCNT1 1999/4885 |
| US-20090203710-A1 | Novel piperidine derivative | HRH3, OPRM1, HRH4 | HRH3 1/4885DYRK3 4284/4885CCNT1 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.